Major criteria for vitiligo include spread or active disease, involvement of highly visible or high-impact areas, psychological distress

Phase 3 studies show the highly selective oral tyrosine kinase 2 inhibitor provides rapid, durable skin improvement

Benefits include total and facial repigmentation in patients 12 years and older versus placebo

Ixekizumab plus tirzepatide tied to simultaneous benefit of American College of Rheumatology 50 percent improvement and weight reduction

Findings seen for skin clearance and disease severity with both every-four-week and every-12-week dosing

Topical melatonin improves hydration and firmness and reduces wrinkle depth and surface roughness in clinical studies

Sensitivity of DERM+ for identifying melanoma was 93.7 percent and for SCC, BCC was 100 and 99.2 percent

Authors say universal screening of all children with atopic dermatitis is unlikely to improve identification of early cardiovascular risk

Higher superficial SSI, deep SSI, wound complications, sepsis, aseptic revision reported for those with cutaneous psoriasis

Mean Total Improvement Score significantly improved at week 52; brepocitinib was superior for all nine secondary outcomes

Topical timolol maleate 0.5 percent gel applied three times daily for 24 weeks is effective and safe

Patients with CLL have increased risk for most skin cancer subtypes and higher risk for skin cancer-specific metastasis and death

Experts warn tanning beds raise skin cancer risk

Icotyde is the first and only targeted oral peptide that blocks the IL-23 receptor

Perioperative and postoperative RT yield equivalent cosmetic outcomes at 18 months postoperatively

Higher sensitivity and specificity seen in single study reporting on AI-assisted dermatologists

Significantly reduced risk for death from melanoma and reduced risk for recurrence reported for those undergoing SNB

Androgenetic alopecia linked to DM, impaired fasting glucose in adults younger 45 years but not those older than 45 years

No significant differences seen in transepidermal water loss, epidermal thickness for AD versus healthy skin at weeks 16 and 28

Atopic dermatitis signs/symptoms continued to improve at treatment week 56 among children aged 2 to 5 years

Patients receiving pembrolizumab or nivolumab exhibited modest reduction in exacerbation rates at 24 months

Findings depend on how expensive a sunscreen people buy and how much of their skin they protect with hats and clothing

Compared with placebo, Sotyktu significantly improves disease activity and quality of life